<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001993</url>
  </required_header>
  <id_info>
    <org_study_id>057A</org_study_id>
    <secondary_id>NS8-90-02-004</secondary_id>
    <nct_id>NCT00001993</nct_id>
  </id_info>
  <brief_title>Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or &gt; 200 to = or &lt; 500 CD4+ Cells/mm3</brief_title>
  <official_title>Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or &gt; 200 to = or &lt; 500 CD4+ Cells/mm3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G D Searle</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the preliminary efficacy and tolerability&#xD;
      of combining a selected dose of SC-48334 with low-dose AZT in the treatment of symptomatic&#xD;
      HIV+ patients with 200 to 500 CD4+ cells/mm3.&#xD;
&#xD;
      The secondary objective is to determine the pharmacokinetics and bioavailability of both&#xD;
      SC-48334 and AZT, when administered together, in symptomatic HIV+ patients with 200 - 500&#xD;
      CD4+ cells/mm3.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>120</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Butyldeoxynojirimycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Medications for the prophylaxis of opportunistic infections, such as:&#xD;
&#xD;
          -  Aerosolized pentamidine.&#xD;
&#xD;
          -  Trimethoprim/sulfamethoxazole.&#xD;
&#xD;
          -  Nystatin.&#xD;
&#xD;
          -  Clotrimazole.&#xD;
&#xD;
          -  Anti-mycobacterial agents.&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
          -  Topical acyclovir.&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  CD4+ cells counts = or &gt; 200 &lt; 500 /cell mm3.&#xD;
&#xD;
          -  For purposes of inclusion the absolute CD4+ cell count must be = or &gt; 200 &lt; 500&#xD;
             cells/mm3 on the first sample and = or &gt; 190 &lt; 510 cells/mm3 on the second sample.&#xD;
&#xD;
          -  Have at least one of the following:&#xD;
&#xD;
          -  Oral candidiasis.&#xD;
&#xD;
          -  Herpes zoster during the last 3 years.&#xD;
&#xD;
          -  Oral hairy leukoplakia during the past three years.&#xD;
&#xD;
          -  Chronic ( &gt; 30 day period), recurrent seborrheic dermatitis, or topical, pruritic&#xD;
             folliculitis (itchy bumps).&#xD;
&#xD;
          -  Unintentional weight loss in excess of 10 pounds or 10 percent of usual body weight.&#xD;
&#xD;
          -  Chronic fatigue present for the past 6 months, which has interfered with normal&#xD;
             activity at least 1 to 2 times per week.&#xD;
&#xD;
          -  HIV antibody positive as determined by federally licensed Enzyme-linked Immunosorbent&#xD;
             Assay (ELISA).&#xD;
&#xD;
          -  Documented, written informed consent must be obtained prior to admission to the study.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed for no more than 12 weeks prior to study entry:&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Malignancies, with the exception of basal cell carcinoma.&#xD;
&#xD;
          -  Significant organ dysfunction.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  All anti-retroviral drugs with the exception of Zidovudine. Cancer chemotherapeutic&#xD;
             agents.&#xD;
&#xD;
          -  Anti-metabolites and alkylating agents.&#xD;
&#xD;
          -  All investigational non-FDA approved drugs.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Clinically significant diarrhea (&gt; 3 liquid stools per day for &gt; 7 days) without&#xD;
             definable cause, within 6 months prior to enrollment).&#xD;
&#xD;
          -  Diarrhea, as above, with known, non-HIV related cause occurring within one month prior&#xD;
             to enrollment.&#xD;
&#xD;
          -  Meets CDC criteria for AIDS classification.&#xD;
&#xD;
          -  Chronic fever (&gt; 38.5 C persisting for more than 14 consecutive days, or for more than&#xD;
             15 days in any 30-day interval prior to study entry).&#xD;
&#xD;
          -  Malignancies, with the exception of basal cell carcinoma.&#xD;
&#xD;
          -  Significant organ dysfunction.&#xD;
&#xD;
          -  Known hypersensitivity to SC-48334 or related compounds.&#xD;
&#xD;
          -  History of lactose intolerance.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 30 days of study entry:&#xD;
&#xD;
          -  Any investigational medication.&#xD;
&#xD;
          -  Treatment with a drug (other than Zidovudine) with anti-HIV activity.&#xD;
&#xD;
          -  Excluded for &gt; 12 weeks prior to study entry:&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Excluded within 90 days of study entry:&#xD;
&#xD;
          -  Ribavirin.&#xD;
&#xD;
          -  Excluded within 6 months of study entry:&#xD;
&#xD;
          -  Cancer chemotherapy.&#xD;
&#xD;
          -  Excluded:&#xD;
&#xD;
          -  Treatment with SC-48334.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 30 days of study entry:&#xD;
&#xD;
          -  Electron beam radiation.&#xD;
&#xD;
          -  Excluded within 6 months prior to study entry:&#xD;
&#xD;
          -  Required HIV-related blood transfusions.&#xD;
&#xD;
          -  Whole body radiation.&#xD;
&#xD;
        Current use of illicit substances; or current abuse of alcohol, the use of which would&#xD;
        limit compliance with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Univ of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>331361013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Presbyterian - Saint Luke's Med Ctr</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Research Clinic / Indiana Univ Hosp</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State Univ Hosp Clinic</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>432101228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Julio Arroyo</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>981224304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fischl MA, Resnick L, Coombs R, Kremer AB, Pottage JC Jr, Fass RJ, Fife KH, Powderly WG, Collier AC, Aspinall RL, et al. The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. J Acquir Immune Defic Syndr (1988). 1994 Feb;7(2):139-47.</citation>
    <PMID>7905523</PMID>
  </reference>
  <verification_date>February 1992</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miglustat</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

